ArticleACS pharmacology & translational science2025
Selective Serotonin Reuptake Inhibitor Fluoxetine Alters Gene Expression Patterns of Sarcoma and Significantly Reduces Tumor Load through Modulation of the Tumor Microenvironment and Restoration of the Host Antitumor Immune System.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective serotonin reuptake inhibitors enhance cancer immunosurveillance by pleiotropic mechanisms.Oncoimmunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effectiveness of cancer therapy is significantly hindered by immunosuppressive mechanisms within the tumor microenvironment (TME). Immunotherapy for cancer leverages the body's immune system, Enhanced immune response to identify, attack, and eliminate tumor cells is the primary goal of immunotherapy. Immune checkpoint blocking, adoptive cell therapy, and cytokine and monoclonal antibody treatments have been reported to achieve significant success in cancer therapy. However, their effectiveness may vary, and immune-related side effects remain a major challenge. In this study, we evaluated the immunomodulatory properties of the selective serotonin reuptake inhibitor (SSRI) fluoxetine. It has been previously reported that fluoxetine exhibits anti-inflammatory properties and has limited effects against cancer; however, a detailed systematic study of the effects of fluoxetine on tumor growth, survival, and the host immune system has not been undertaken. This study evaluates the therapeutic potential of fluoxetine in sarcoma-bearing animals and explores the underlying mechanisms of action. Fluoxetine treatment
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.